THE FDA GRANTED ACCELERATED APPROVAL TO A TARGETED THERAPY FOR PATIENTS WITH CML RESISTANT TO OTHER THERAPEUTICS The U.S. Food and Drug Administration (FDA) approved the drug asciminib (Scemblix) for certain patients with Philadelphia...
THE FDA APPROVED THE FIRST ADJUVANT IMMUNOTHERAPY FOR EARLY LUNG CANCER The U.S. Food and Drug Administration (FDA) granted expanded approval to atezolizumab (Tecentriq) to include the treatment of certain patients with early non-small...
THE FDA APPROVED THE IMMUNE CHECKPOINT INHIBITOR PEMBROLIZUMAB IN COMBINATION AND AS A SINGLE AGENT FOR ADVANCED CERVICAL CANCER The U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with chemotherapy,...
THE FDA APPROVED A NEW TYPE OF CANCER INHIBITOR FOR CERTAIN PATIENTS WITH A HIGH RISK OF RECURRENCE The U.S. Food and Drug Administration (FDA) approved abemaciclib (Verzenio) with endocrine therapy for certain patients...
THE FDA APPROVED THE FIRST CAR-T CELL THERAPY FOR CERTAIN PATIENTS WITH this aggressive form of LEUKEMIA The U.S. Food and Drug Administration (FDA) approved brexucabtagene autoleucel (Tecartus) for certain adult patients with B-cell...
THE FDA GRANTED ACCELERATED APPROVAL TO A NEW THERAPY FOR ADVANCED CERVICAL CANCER The U.S. Food and Drug Administration (FDA) granted accelerated approval to tisotumab vedotin-tftv (Tidvak) for patients with cervical cancer that has...
The FDA approved a tyrosine kinase inhibitor for certain patients with thyroid cancer. The U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) for adult and pediatric patients 12 years of age and older...
The FDA granted accelerated approval to a new targeted therapeutic and companion diagnostic test for certain adult patients with lung cancer. The U.S. Food and Drug Administration (FDA) granted accelerated approval to mobocertinib (Exkivity)...
THE FDA GRANTED ACCELERATED APPROVAL TO ZANUBRUTINIB FOR CERTAIN ADULTS WITH MARGINAL ZONE LYMPHOMA The U.S. Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib (Brukinsa) for certain adult patients with marginal zone...
The FDA approved zanubrutinib, a tyrosine kinase inhibitor, for this form of non-Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) approved zanubrutinib (Brukinsa) for adult patients with Waldenström macroglobulinemia, a slow-growing form of...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More